Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails – such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA ...
Aug 28, 2012
0
0
A Singapore research team of clinicians and scientists has validated a cancer diagnostic assay designed with Asian-centric biomarkers that aims to enable early diagnosis and timely treatment delivery. These findings, published ...
Oct 14, 2022
0
10
A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel ...
Oct 2, 2019
0
3
The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest ...
Apr 7, 2014
0
0
Research led by the St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with ...
Nov 12, 2012
0
0
(Medical Xpress)—A test used to detect a type of cancer in children may produce false positives because it is based on a faulty assumption, researchers at the University of Virginia School of Medicine have determined.
Jan 24, 2014
0
0
(HealthDay)—The fibroblast growth factor receptor 3 (FGFR3) transforming acidic coiled-coil containing protein 3 (TACC3) (FT3) gene fusion recruits endogenous TACC3 away from the mitotic spindle, resulting in errors in ...
Sep 18, 2017
0
1
Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the San Antonio Breast ...
Dec 8, 2023
0
0
A study by the University of Warwick sheds new light on gene fusion in bladder and brain cancer.
Aug 30, 2017
0
1
The investigational anticancer therapeutic LOXO-101, which targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), was safe, tolerable, and showed signs of clinical activity in patients who had ...
Nov 9, 2015
0
3
